All Categories

Transient abnormal myelopoiesis requiring advanced neonatal intensive care treatment

Maria Chalia, Emilie Seager, Anupama Rao, Simon HannamGreat Ormond Street Hospital for Children.United Kingdom Acta PaediatricaActa Paediatr 2024; DOI: 10.1111/apa.17142 AbstractAim: Five to thirty percent of neonates with trisomy 21 develop transient abnormal myelopoiesis (TAM) with a high mortality rate. The aim of the study was to identify contributing factors that determine mortality and need for chemotherapy […]

Transient abnormal myelopoiesis requiring advanced neonatal intensive care treatment Read More »

[Clinical and genetic analysis of a patient with HUPRA syndrome due to missense variants of SARS2 gene and literature review]

J. Huang, Q. Y. Li. W. Ji, X.F. Guo, X. H. HuFujian Children’s Hospital. Beijing Anzhen Hospital and Capital Medical University. Shanghai Jiaotong University School of Medicine and Shanghai Children’s Medical Center. Fujian Provincial Maternity and Children’s Hospital. Xinhua Hospital.China Zhonghua Xin Xue Guan Bing Za Zhi 2024; 52: 172-179DOI: 10.3760/cma.j.cn112148-20231009-00268 Abstract (English)Objective: To explore the clinical

[Clinical and genetic analysis of a patient with HUPRA syndrome due to missense variants of SARS2 gene and literature review] Read More »

Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension

Michael W. Cookson, John P. KinsellaUniversity of Colorado Anschutz School of Medicine and Children’s Hospital Colorado.United States Clinics in PerinatologyClin Perinatol 2024; 51: 95-111DOI: 10.1016/j.clp.2023.11.001 AbstractPivotal trials investigating the use of inhaled nitric oxide (iNO) in the 1990s led to approval by the Food and Drug Administration in 1999. Inhaled nitric oxide is the only approved

Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension Read More »

Oxygen Targets in Neonatal Pulmonary Hypertension: Individualized, “Precision-Medicine” Approach

Satyan Lakshminrusimha, Steven H. AbmanUniversity of California, Davis Children’s Hospital. University of Colorado Anschutz Medical Campus.United States Clinics in PerinatologyClin Perinatol 2024; 51: 77-94DOI: 10.1016/j.clp.2023.12.003 AbstractOxygen is a specific pulmonary vasodilator. Hypoxemia causes pulmonary vasoconstriction, and normoxia leads to pulmonary vasodilation. However, hyperoxia does not enhance pulmonary vasodilation but causes oxidative stress. There are no clinical

Oxygen Targets in Neonatal Pulmonary Hypertension: Individualized, “Precision-Medicine” Approach Read More »

Comorbidities and Late Outcomes in Neonatal Pulmonary Hypertension

Emily S. Stieren, Deepika Sankaran, Satyan Lakshminrusimha, Catherine A. RottkampUniversity of California, Davis.United States Clinics in PerinatologyClin Perinatol 2024; 51: 271-289DOI: 10.1016/j.clp.2023.10.002 AbstractLong-term outcomes of persistent pulmonary hypertension of newborn (PPHN) depend on disease severity, duration of ventilation, and associated anomalies. Congenital diaphragmatic hernia survivors may have respiratory morbidities and developmental delay. The presence of PPHN

Comorbidities and Late Outcomes in Neonatal Pulmonary Hypertension Read More »

Randomized Controlled Trials of Pulmonary Vasodilator Therapy Adjunctive to Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn: A Systematic Review

Kristen Coletti, K. Taylor Wild, Elizabeth E. Foglia, Suzan Cochius-den Otter, Haresh KirpalaniChildren’s Hospital of Philadelphia and University of Pennsylvania. Erasmus MC University Medical Center.United States and Netherlands Clinics in PerinatologyClin Perinatol 2024; 51: 253-269DOI: 10.1016/j.clp.2023.11.009 AbstractInhaled nitric oxide (iNO) is a pulmonary vasodilator considered standard of care to treat persistent pulmonary hypertension of the newborn.

Randomized Controlled Trials of Pulmonary Vasodilator Therapy Adjunctive to Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn: A Systematic Review Read More »

Etiology, Diagnosis and Management of Persistent Pulmonary Hypertension of the Newborn in Resource-limited Settings

Prathik Bandiya, Rajeshwari Madappa, Ajay Raghav JoshiSouth Hospital Complex and Dharmaram College Post. SIGMA Hospital. India Clinics in PerinatologyClin Perinatol 2024; 51: 237-252DOI: 10.1016/j.clp.2023.11.002 AbstractPersistent Pulmonary Hypertension of the Newborn (PPHN) is more common in low and middle income countries (LMICs) due to high incidence of sepsis, perinatal asphyxia and meconium aspiration syndrome. Presence of hypoxic

Etiology, Diagnosis and Management of Persistent Pulmonary Hypertension of the Newborn in Resource-limited Settings Read More »

Pulmonary Hypertension in Developmental Lung Diseases

Olivier Danhaive, Csaba Galambos, Satyan Lakshminrusimha, Steven H. AbmanSaint-Luc University Hospital and University of California San Francisco. University of Colorado Anschutz School of Medicine. University of California, UC Davis Children’s Hospital.Belgium and United States Clinics in PerinatologyClin Perinatol 2024; 51: 217-235DOI: 10.1016/j.clp.2023.12.001 AbstractDiverse genetic developmental lung diseases can present in the neonatal period with hypoxemic respiratory

Pulmonary Hypertension in Developmental Lung Diseases Read More »

Pathogenesis and Physiologic Mechanisms of Neonatal Pulmonary Hypertension: Preclinical Studies

Karen C. Young, Augusto F. Schmidt, April W. Tan, Lourenco Sbragia, Ahmed Elsaie, Binoy ShivannaUniversity of Miami Miller School of Medicine. Ribeirao Preto Medical School. Ascension Via Christi St. Joseph Hospital and Cairo University. Baylor College of Medicine.United States, Brazil and Egypt Clinics in PerinatologyClin Perinatol 2024; 51: 21-43DOI: 10.1016/j.clp.2023.11.004 AbstractNeonatal pulmonary hypertension (PH) is a

Pathogenesis and Physiologic Mechanisms of Neonatal Pulmonary Hypertension: Preclinical Studies Read More »

Pulmonary Hypertension in Established Bronchopulmonary Dysplasia: Physiologic Approaches to Clinical Care

Steven H. Abman, Satyan LakshminrusimhaUniversity of Colorado Anschutz Medical Campus. University of California, Davis Children’s Hospital.United States Clinics in PerinatologyClin Perinatol 2024; 51: 195-216DOI: 10.1016/j.clp.2023.12.002 AbstractPreterm infants with bronchopulmonary dysplasia (BPD) are prone to develop pulmonary hypertension (PH). Strong laboratory and clinical data suggest that antenatal factors, such as preeclampsia, chorioamnionitis, oligohydramnios, and placental dysfunction leading

Pulmonary Hypertension in Established Bronchopulmonary Dysplasia: Physiologic Approaches to Clinical Care Read More »

Scroll to Top